Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aptose Biosciences Inc.
Report date June 30, 2026 · Filed July 01, 2026
Section 16 reporting ended · disclosed 2026-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Disposition to issuer · Disposed 70 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F2: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2034-02-05 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-30 · Disposition to issuer · Disposed 3,333 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2032-01-17 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-30 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.37 · Expires 2031-01-04 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-30 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.15 · Expires 2030-03-10 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-30 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.91 · Expires 2030-01-30 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-30 · Disposition to issuer · Disposed 160,334 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2027-06-06 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-06-30 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2028-01-19 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-30 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2027-03-28 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2029-01-02 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-30 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share.
F2: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
CytoDyn Inc.
Report date July 12, 2018 · Filed November 16, 2018
Section 16 reporting ended · disclosed 2018-11-16. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 11 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,000 shares Expires 2027-03-28 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 10 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 60,000 shares Expires 2028-01-19 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 9 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,000 shares Expires 2027-06-06 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 8 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,000 shares Expires 2029-01-02 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 160,334 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 7 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 160,334 shares Expires 2030-01-30 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 6 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2030-03-10 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 5 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2031-01-04 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 4 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2032-01-17 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 3 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 100,000 shares Expires 2033-01-19 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · derivative · entry 2 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,333 shares Expires 2034-02-05 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerCommon Shares | 70 | $1.72 | $120.40 |
DisclosureSEC source: 0000912282-26-000894 · form4.xml · nonDerivative · entry 1 BURGER DENIS R · CIK 0001239414 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. F2 · price: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:39 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000912282-24-000118 · form4.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Shares · 3,333 shares Expires 2034-02-05 F1 · derivative.exercise_date: The options vest as follows: 50% on February 5, 2025; 25% on February 5, 2026; and 25% on February 5, 2027. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:53 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001567619-23-001157 · doc1.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2033-01-19 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on January 19, 2024, twenty-five percent (25%) vest on January 19, 2025, and twenty-five percent vest on January 19, 2026. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:14 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-22-001376 · doc1.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: The options were granted on January 18, 2022, and vest as follows: 50% vest on January 18, 2023; 25% vest on January 18, 2024; and 25% vest on January 18, 2025. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 16:19 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | PurchaseCommon Shares | 10,000 | $1.45 | $14,490.00 |
DisclosureSEC source: 0001567619-21-022365 · doc1.xml · nonDerivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,671 Read SEC document |
| November 19, 2021 Filed Nov 20, 2021 01:42 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 5,714 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001567619-21-020908 · doc1.xml · derivative · entry 2 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,714 shares Expires 2021-11-29 F1 · derivative.exercise_price: Converted from Canadian exercise price of C$2.58 using an exchange rate of C$1.2639 = US$1.00. Read SEC document |
| November 19, 2021 Filed Nov 20, 2021 01:42 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Exercise / conversionCommon Shares | 5,417 | $2.04 | $11,050.68 |
DisclosureSEC source: 0001567619-21-020908 · doc1.xml · nonDerivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 20:32 UTC Amendment | Aptose Biosciences Inc. APTO · Entity 33387 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 5,417 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001567619-21-021040 · doc1.xml · derivative · entry 2 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,417 shares Expires 2021-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted from Canadian exercise price of C$2.58 using an exchange rate of C$1.2639 = US$1.00. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 20:32 UTC Amendment | Aptose Biosciences Inc. APTO · Entity 33387 | Exercise / conversionCommon Shares | 5,417 | $2.04 | $11,050.68 |
DisclosureSEC source: 0001567619-21-021040 · doc1.xml · nonDerivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:51 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001567619-21-000593 · doc1.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The options were granted on January 4, 2021, and vest as follows: 50% vest on January 4, 2022; 25% vest on January 4, 2023; and 25% vest on January 4, 2024. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 00:38 UTC Amendment | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Option Grant · Derivative | 50,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001567619-20-006347 · doc1.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-03-10 Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 23:44 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Option Grant · Derivative | 50,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001567619-20-006339 · doc1.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-03-10 F1 · derivative.exercise_price: Converted from Canadian exercise price of C$7.08 using an exchange rate of 1.3745. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 02:39 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Option Grant · Derivative | 160,334 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001567619-20-001976 · doc1.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,334 Underlying: Common Shares · 160,334 shares Expires 2030-01-30 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on 1/31/2021. The remaining 50% vest as follows: one-half on 1/31/2022 and one-half on 1/31/2023. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 01:12 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001567619-19-000425 · doc1.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The options vest fully on the first anniversary of the grant. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 21:56 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0000899243-18-016230 · doc4.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 80,331 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-003452 · doc4.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,331 Underlying: Common Stock · 80,331 shares Expires 2028-02-07 F1 · price: On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:45 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000899243-17-015351 · doc4.xml · derivative · entry 2 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2027-06-01 F2 · derivative.exercise_date: Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, one third of the options will vest on each date that is six months, 18 months and 30 months following the grant date. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:45 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000899243-17-015351 · doc4.xml · derivative · entry 1 BURGER DENIS R · CIK 0001239414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.